Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Verastem Oncology Is Tanking Today

By Cory Renauer – Apr 27, 2020 at 1:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Details from a clinical trial with the company's latest lead candidate weren't what investors had hoped for.

What happened

Shares of Verastem Oncology (VSTM -8.67%), a biotechnology company developing novel cancer therapies, are sliding after a highly anticipated data drop failed to impress investors. Shares of the biotech stock were down 42.9% as of 12:12 p.m. EDT on Monday.

So what

This year, the American Association for Cancer Research granted independent researchers who have been testing a combination of Verastem's experimental therapies a virtual poster presentation during this year's meeting. Verastem shares ballooned last week after the company told investors it would hold a conference call today to discuss results of an independently sponsored clinical trial that used VS-6766 plus defactinib to treat cancer patients with aggressive tumors driven by the same mutation.

Person looking at a downward-sloping chart arrow crashing through the floor.

Image source: Getty Images.

The stock is tanking today because there wasn't much to be excited about, at least from an investor's viewpoint. Among 10 lung cancer patients in the study with KRAS-mutant tumors, just 1 showed signs of tumor shrinkage.

Now what

Tumors driven by KRAS mutations are difficult to treat, but not for lack of trying. Amgen (AMGN -0.34%) and Mirati Therapeutics (MRTX -2.52%) are both running clinical trials with drugs aimed at this target, and both have notched a great deal more success than Verastem's candidates.

Despite seemingly unbeatable competition from Amgen and Mirati for lung cancer patients, Verastem will probably try to convince investors there's a future for VS-6766 as an ovarian cancer treatment. Four out of six patients with KRAS-mutant-positive ovarian cancer responded to treatment with VS-6766 plus defactinib.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Verastem, Inc. Stock Quote
Verastem, Inc.
VSTM
$0.92 (-8.67%) $0.09
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$226.97 (-0.34%) $0.78
Mirati Therapeutics, Inc. Stock Quote
Mirati Therapeutics, Inc.
MRTX
$68.18 (-2.52%) $-1.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.